
Doximity (DOCS) Stock Forecast & Price Target
Doximity (DOCS) Analyst Ratings
Bulls say
Doximity is likely to face revenue headwinds in the coming years due to a declining number of pharmaceuticals under patent, reducing the need for high levels of marketing spend on its platform. This could negatively impact the company's core marketing solutions segment, and its recent appointment of a new CFO and president may be a response to these challenges. In addition, the company has announced weaker market conditions and reduced market share gains, cutting their FY27 and FY28 estimates, with F1Q guidance below consensus. This is likely due to ongoing policy uncertainty and increased macro risk, as well as pharma companies shifting towards shorter-duration spend commitments resulting in limited visibility.
Bears say
Doximity is facing significant challenges due to market pressure and investments in AI that have led to lower than expected guidance for FY27 and 1QF27, despite projected revenue growth of 17.5%. In addition, their EBITDA guidance is also lower than expected, but they plan to maintain a high adjusted EBITDA margin. However, concerns about inconsistent results and competition have prompted a downgrade to Neutral, while competitor VEEV has a Buy rating and is successfully navigating industry challenges. Despite risks in the regulated healthcare industry, DOCS may see potential upside from increased demand for AI solutions and new leadership in a post-pandemic world.
This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.
Doximity (DOCS) Analyst Forecast & Price Prediction
Start investing in Doximity (DOCS)
Order type
Buy in
Order amount
Est. shares
0 shares